Study Findings on Alzheimer Disease Are Outlined in Reports from Panjab University (Bacopa Monnieri Prevents Colchicine-induced Dementia By Anti-inflammatory Action)
Daily India Report
2019 APR 26 (NewsRx) -- By a News Reporter-Staff News Editor at Daily India Report -- Research findings on Neurodegenerative Diseases and Conditions - Alzheimer Disease are discussed in a new report. According to news reporting originating from Chandigarh, India, by NewsRx correspondents, research stated, “Inflammation is considered as an early event in the development of Alzheimer’s disease (AD) that precedes the formation of A plaques and neurofibrillary tangles. Therefore, strategies aimed at attenuating inflammation by phytochemicals may be a potential therapeutic intervention against AD.”
Financial support for this research came from Department of Science and Technology (DST), New Delhi.
Our news editors obtained a quote from the research from Panjab University, “The present study was designed to evaluate if colchicine-induced inflammation and A production could be prevented by Bacopa monnieri (BM) supplementation. Dementia was induced by a single intracerebroventicular injection of colchicine (15g/5l), whereas, BM extract was administered orally (50mg/kg body weight, daily) for 15days. Assessment of cognitive functions using Morris water maze revealed deficits in colchicine administered animals. This was accompanied by significant increase in oxidative stress in terms of accentuated ROS and NO production. Expression of pro-inflammatory cytokines (IL-6, TNF-) and chemokine (MCP-1) increased in the brain regions. Furthermore, COX-2 and iNOS expression also increased significantly in the brain regions of colchicine-administered animals. In addition, BACE-1 activity increased in the colchicine treated animals, which was accompanied by enhanced A production. On the other hand, BM supplementation was able to improve cognitive functions, suppress A formation by reducing BACE-1 activity. Inflammatory and oxidative stress markers were attenuated in the brain regions of BM supplemented animals.”
According to the news editors, the research concluded: “Taken together, the findings reveal that BM reverses colchicine-induced dementia by its anti-inflammatory and anti-oxidant action suggesting that it may be an effective therapeutic intervention to ameliorate progression of AD.”
For more information on this research see: Bacopa Monnieri Prevents Colchicine-induced Dementia By Anti-inflammatory Action. Metabolic Brain Disease, 2019;34(2):505-518. Metabolic Brain Disease can be contacted at: Springer, Plenum Publishers, 233 Spring St, New York, NY 10013, USA. (Springer - www.springer.com; Metabolic Brain Disease - http://www.springerlink.com/content/0885-7490/)
The news editors report that additional information may be obtained by contacting R. Sandhir, Panjab University, Dept. of Biochemistry, Chandigarh 160014, India. Additional authors for this research include N. Saini and D. Singh.
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1007/s11011-018-0332-1. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
(Our reports deliver fact-based news of research and discoveries from around the world.)